In today’s briefing:
- Meituan (3690 HK): Online Drug Sales Is the First Sweet Spot of O2O Vs. E-Commerce
- Elanco Animal Health: Innovation-Led Portfolio Expansion Fueling Our ‘Buy’ Rating! – Major Drivers
- Fresenius Medical Care’s Bold Turnaround: How Care Delivery & Enablement Are Redefining Profitability! – Major Drivers
- Medpace Holdings: Dealing With Funding Dynamics & Critical Market Challenges! – Major Drivers
Meituan (3690 HK): Online Drug Sales Is the First Sweet Spot of O2O Vs. E-Commerce
- O2O has made a huge impact on China’s e-commerce scene in 2024. The Coupang-invented model suits mega cities with dense population and order volumes;
- Online drug O2O, in particular, has gained momentum because drugs, prescription and non-prescription have robust storage and distribution needs on the ground for O2O use;
- Meituan’s drug sales has grown its overall market share from 3.6% in 2022 to 7.1% in 2024. We project it to grow to 12.3% by 2030.
Elanco Animal Health: Innovation-Led Portfolio Expansion Fueling Our ‘Buy’ Rating! – Major Drivers
- Elanco Animal Health’s third-quarter 2024 performance presents a mix of achievements and challenges that form the basis of an investment perspective.
- The company reported a modest 1% organic constant currency revenue growth, driven by contributions from new products like Experior, Adtab, Credelio Plus, and Zenrelia.
- This quarter marked the fifth consecutive one that Elanco has demonstrated growth in its underlying business.
Fresenius Medical Care’s Bold Turnaround: How Care Delivery & Enablement Are Redefining Profitability! – Major Drivers
- Fresenius Medical Care demonstrated steady progress in its operational and financial performance during the third quarter, reflecting a focused transformation strategy and resilience amid external challenges.
- The company reported organic revenue growth of 2%, with positive contributions from both Care Delivery and Care Enablement segments.
- Notably, the U.S. same-market treatment growth turned marginally positive at 0.2%, marking a significant milestone, though still tempered by elevated mortality rates.
Medpace Holdings: Dealing With Funding Dynamics & Critical Market Challenges! – Major Drivers
- Medpace Holdings, Inc. reported its third-quarter 2024 earnings, showcasing a mixed bag of results influenced by both positive performance metrics and notable challenges.
- On the earnings call, company leadership discussed these results and the ongoing dynamics impacting its business.
- One of the highlights was Medpace’s revenue for the third quarter, which reached $533.3 million, marking an 8.3% year-over-year increase.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
